Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
García-Barchino, María José
Basheer, Noorjahan Jagalur
Beijersbergen, Roderick L.
Zwaan, C. Michel
Martínez-Climent, José Ángel
AffiliationNetherlands Cancer Institute
University of Navarra
University of Helsinki
Erasmus Medical Center/Sophia Children’s Hospital
Helsinki University Central Hospital
MetadataShow full item record
AbstractAlthough conventional therapies for acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) are effective in inducing remission, many patients relapse upon treatment. Hence, there is an urgent need for novel therapies. PIM kinases are often overexpressed in AML and DLBCL and are therefore an attractive therapeutic target. However, in vitro experiments have demonstrated that intrinsic resistance to PIM inhibition is common. It is therefore likely that only a minority of patients will benefit from single agent PIM inhibitor treatment. In this study, we performed an shRNA-based genetic screen to identify kinases whose suppression is synergistic with PIM inhibition. Here, we report that suppression of p38α (MAPK14) is synthetic lethal with the PIM kinase inhibitor AZD1208. PIM inhibition elevates reactive oxygen species (ROS) levels, which subsequently activates p38α and downstream AKT/mTOR signaling. We found that p38α inhibitors sensitize hematological tumor cell lines to AZD1208 treatment in vitro and in vivo. These results were validated in ex vivo patient-derived AML cells. Our findings provide mechanistic and translational evidence supporting the rationale to test a combination of p38α and PIM inhibitors in clinical trials for AML and DLBCL.
CitationBrunen D, García-Barchino M, Malani D, Basheer N, Lieftink C, Beijersbergen R, Murumägi A, Porkka K, Wolf M, Zwaan CM, Fornerod M, Kallioniemi O, Martínez-Climent J, Bernards R (2016) 'Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling', Oncotarget, 7 (25), pp.37407-37419.
PublisherImpact Journals LLC
PubMed Central IDPMC5122321
SponsorsThis study was supported (in part) by research funding from AstraZeneca to D.B. and R.B. This work was supported by grants from the Dutch Cancer Society, KIKA, KOCR Society Rotterdam, Academy of Finland Centre of Excellence, and Sigrid Juselius Foundation.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
- Authors: Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M
- Issue date: 2015 Nov 10
- Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
- Authors: Chen LS, Yang JY, Liang H, Cortes JE, Gandhi V
- Issue date: 2016 Dec
- Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
- Authors: Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR
- Issue date: 2016 Jul 26
- PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
- Authors: Meja K, Stengel C, Sellar R, Huszar D, Davies BR, Gale RE, Linch DC, Khwaja A
- Issue date: 2014 Oct
- AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
- Authors: Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, Deangelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD, Huszar D
- Issue date: 2014 Feb 6